Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study

• Published in: Journal of the American Heart Association 2022-06, Vol.11 (11), p.e024870-e024870
• Main Authors: Obisesan, Olufunmilayo H, Kou, Minghao, Wang, Frances M, Boakye, Ellen, Honda, Yasuyuki, Uddin, S M Iftekhar, Dzaye, Omar, Osei, Albert D, Orimoloye, Olusola A, Howard-Claudio, Candace M, Coresh, Josef, Blumenthal, Roger S, Hoogeveen, Ron C, Budoff, Matthew J, Matsushita, Kunihiro, Ballantyne, Christie M, Blaha, Michael J
• Format: Article
• Language: English
• Subjects: aortic valve calcium; Atherosclerosis - complications; Atherosclerosis - diagnostic imaging; Atherosclerosis - epidemiology; Calcinosis - diagnostic imaging; Calcinosis - epidemiology; Calcinosis - etiology; Calcium; coronary artery calcium; Coronary Artery Disease - complications; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - epidemiology; extra‐coronary calcification; Female; Heart Valve Diseases - complications; Heart Valve Diseases - diagnostic imaging; Heart Valve Diseases - epidemiology; Humans; Lipoprotein(a); Male; Middle Aged; Original Research; Risk Factors; subclinical atherosclerosis; Tomography, X-Ray Computed - methods; Vascular Calcification - complications; Vascular Calcification - diagnostic imaging; Vascular Calcification - epidemiology
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.121.024870

Background Lipoprotein(a) (Lp(a)) is a potent causal risk factor for cardiovascular events and mortality. However, its relationship with subclinical atherosclerosis, as defined by arterial calcification, remains unclear. This study uses the ARIC (Atherosclerosis Risk in Communities Study) to evaluate the relationship between Lp(a) in middle age and measures of vascular and valvular calcification in older age. Methods and Results Lp(a) was measured at ARIC visit 4 (1996-1998), and coronary artery calcium (CAC), together with extracoronary calcification (including aortic valve calcium, aortic valve ring calcium, mitral valve calcification, and thoracic aortic calcification), was measured at visit 7 (2018-2019). Lp(a) was defined as elevated if >50 mg/dL and CAC/extracoronary calcification were defined as elevated if >100. Logistic and linear regression models were used to evaluate the association between Lp(a) and CAC/extracoronary calcification, with further stratification by race. The mean age of participants at visit 4 was 59.2 (SD 4.3) years, with 62.2% women. In multivariable adjusted analyses, elevated Lp(a) was associated with higher odds of elevated aortic valve calcium (adjusted odds ratio [aOR], 1.82; 95% CI, 1.34-2.47), CAC (aOR, 1.40; 95% CI, 1.08-1.81), aortic valve ring calcium (aOR, 1.36; 95% CI, 1.07-1.73), mitral valve calcification (aOR, 1.37; 95% CI, 1.06-1.78), and thoracic aortic calcification (aOR, 1.36; 95% CI, 1.05-1.77). Similar results were obtained when Lp(a) and CAC/extracoronary calcification were examined on continuous logarithmic scales. There was no significant difference in the association between Lp(a) and each measure of calcification by race or sex. Conclusions Elevated Lp(a) at middle age is significantly associated with vascular and valvular calcification in older age, represented by elevated CAC, aortic valve calcium, aortic valve ring calcium, mitral valve calcification, thoracic aortic calcification. Our findings encourage assessing Lp(a) levels in individuals with increased cardiovascular disease risk, with subsequent comprehensive vascular and valvular assessment where elevated.